Browsing: Ascletis

The company’s two core hepatitis drugs were dropped from China’s state insurance scheme on July 1, effectively wiping out the remains of its legacy drug sales

–  ASC36_35 FDC, a once-monthly subcutaneous (SQ) injection co-formulation of ASC36 and ASC35, is a potentially first-in-class drug candidate targeting three validated targets of amylin receptor, GLP-1R and GIPR

Ascletis files two FDA INDs for once-monthly obesity drugs targeting amylin, GLP-1R, and GIPR

Ascletis Pharma (SEHK:1672) recently received U.S. FDA Investigational New Drug clearance to begin a Phase I trial of ASC35, a once monthly GLP-1R/GIPR dual agonist for obesity treatment

July 5, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today recent submissions of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for ASC36, a once-monthly to once-quarterly next-generation peptide amylin receptor agonist and ASC36_35 FDC, a once-monthly injection co-formulation of ASC36 plus peptide GLP-1R/GIPR agonist ASC35,…